Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

A meta-analysis of XPD/ERCC2 Lys751Gln polymorphism and melanoma susceptibility.

Sun Y, Zhang H, Ying H, Jiang W, Chen Q.

Int J Clin Exp Med. 2015 Aug 15;8(8):13874-8. eCollection 2015.

2.

A meta-analysis of XPC Lys939Gln polymorphism and melanoma susceptibility.

Jiang W, Zhang H, Chen QW, Xie S.

J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1327-31. doi: 10.1111/jdv.13477. Epub 2015 Nov 9.

PMID:
26551988
3.

Association between XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma risk: a systematic review and meta-analysis.

Peng Q, Li S, Lao X, Chen Z, Li R, Qin X.

Medicine (Baltimore). 2014 Dec;93(29):e330. doi: 10.1097/MD.0000000000000330. Review.

4.

XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies.

Ding DP, Ma WL, He XF, Zhang Y.

Mol Biol Rep. 2012 Mar;39(3):2533-40. doi: 10.1007/s11033-011-1005-x. Epub 2011 Jun 11.

PMID:
21667112
5.

Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.

Yang R, Zhang C, Malik A, Shen ZD, Hu J, Wu YH.

World J Gastroenterol. 2014 Nov 28;20(44):16765-73. doi: 10.3748/wjg.v20.i44.16765. Review.

6.

XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies.

Zhu HL, Bao JM, Lin PX, Li WX, Zou ZN, Huang YE, Chen Q, Shen H.

Asian Pac J Cancer Prev. 2014;15(16):6619-25.

7.

XPD Lys751Gln polymorphism is not associated with oral cancer risk: evidence from a meta-analysis.

Cui J, Li D, Shen L, Zhang W, Xu X.

Tumour Biol. 2014 Jul;35(7):6335-41. doi: 10.1007/s13277-014-1835-y. Epub 2014 Mar 22.

PMID:
24652592
8.
9.

XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.

Qiu LX, Yao L, Zhang J, Zhu XD, Zhao XM, Xue K, Mao C, Chen B, Zhan P, Yuan H, Hu XC.

Breast Cancer Res Treat. 2010 Nov;124(1):229-35. doi: 10.1007/s10549-010-0813-3. Epub 2010 Mar 5.

PMID:
20204500
10.

ERCC2 Lys751Gln polymorphism is associated with lung cancer among Caucasians.

Zhang J, Gu SY, Zhang P, Jia Z, Chang JH.

Eur J Cancer. 2010 Sep;46(13):2479-84. doi: 10.1016/j.ejca.2010.05.008. Epub 2010 Jun 3. Review.

PMID:
20627704
11.

Polymorphisms of excision repair gene XPD Lys751Gln and hOGG1 Ser326Cys might not be associated with hepatocellular carcinoma risk: a meta-analysis.

Zhang RC, Mou SH.

Tumour Biol. 2013 Apr;34(2):901-7. doi: 10.1007/s13277-012-0625-7. Epub 2012 Dec 28. Retraction in: Tumour Biol. 2017 Apr 20;:.

PMID:
23271362
12.

Lack of association between the XPD Lys751Gln polymorphism and colorectal cancer risk: a meta-analysis.

Zhang T, Zhang DM, Zhao D, Hou XM, Ma SC, Liu XJ.

Onco Targets Ther. 2014 Jul 12;7:1255-60. doi: 10.2147/OTT.S66291. eCollection 2014.

13.

XPD Lys751Gln polymorphisms and the risk of esophageal cancer: an updated meta-analysis.

Guo XF, Wang J, Lei XF, Zeng YP, Dong WG.

Intern Med. 2015;54(3):251-9. doi: 10.2169/internalmedicine.54.3256.

14.

Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis.

Yuan H, Niu YM, Wang RX, Li HZ, Chen N.

Genet Mol Res. 2011 Nov 22;10(4):3356-64. doi: 10.4238/2011.November.22.6.

15.

XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies.

Yin QH, Liu C, Hu JB, Meng RR, Li L, Wang YJ.

Asian Pac J Cancer Prev. 2013;14(1):231-6.

16.

Association of XPD Lys751Gln polymorphism with head and neck cancer susceptibility: evidence from 11,443 subjects.

Lin H, Lin D, Zheng C.

Diagn Pathol. 2014 Jan 20;9:15. doi: 10.1186/1746-1596-9-15.

17.

Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.

Zhang Y, Ding D, Wang X, Zhu Z, Huang M, He X.

Int J Colorectal Dis. 2011 Oct;26(10):1257-64. doi: 10.1007/s00384-011-1222-8. Epub 2011 May 4.

PMID:
21541661
18.

Association of ERCC1 C8092A and ERCC2 Lys751Gln polymorphisms with the risk of glioma: a meta-analysis.

Xin Y, Hao S, Lu J, Wang Q, Zhang L.

PLoS One. 2014 Apr 24;9(4):e95966. doi: 10.1371/journal.pone.0095966. eCollection 2014.

19.

Associations Between XPD Lys751Gln Polymorphism and Leukemia: A Meta-Analysis.

Wen M, Zhou B, Lin X, Chen Y, Song J, Li Y, Zacksenhaus E, Ben-David Y, Hao X.

Front Genet. 2018 Jun 14;9:218. doi: 10.3389/fgene.2018.00218. eCollection 2018.

20.

Association between XPD Lys751Gln polymorphism and bladder cancer susceptibility: an updated and cumulative meta-analysis based on 6,836 cases and 8,251 controls.

Li S, Zeng XT, Ruan XL, Liu TZ, Wang XH.

Mol Biol Rep. 2014 Jun;41(6):3621-9. doi: 10.1007/s11033-014-3226-2. Epub 2014 Feb 8.

PMID:
24510389

Supplemental Content

Support Center